This study is about a treatment for melanoma (a type of skin cancer) that has spread to the brain. The treatment involves using a special kind of radiation called stereotactic radiosurgery (SRS), which targets brain tumors very precisely. It also uses medications called immune checkpoint inhibitors to help the body's immune system fight cancer cells. Another part of the treatment is a device called NovoTTF-100M that sends electric fields to the tumor to stop cancer cells from dividing.
The study aims to see if using all three treatments together is safe and more effective than using just SRS and immune checkpoint inhibitors. Participants will be monitored for side effects and how well the cancer responds to treatment. The study requires regular visits and uses the NovoTTF-100M device for about 8 hours daily.
- Duration: After treatment, follow-up lasts 28 days.
- Requirements: Participants must be 22 years or older and have melanoma that has spread to the brain.
- Compensation: Information on compensation is not provided.